Interestingly, patients in group 2 —characterised by low expression of all five biomarkers— had moderate to severe disease and poor responses to immunosuppressive and anti‐TNF therapy, suggesting that the use of these biomarkers to classify Crohn's disease patients could help predict disease behaviour and response to therapy 206. This evidence concerns the gene TNF and Crohn disease.